Eads & Heald Wealth Management Trims Stake in Pfizer Inc. (NYSE:PFE)

Eads & Heald Wealth Management lowered its stake in Pfizer Inc. (NYSE:PFE) by 37.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,142 shares of the biopharmaceutical company’s stock after selling 4,803 shares during the quarter. Eads & Heald Wealth Management’s holdings in Pfizer were worth $234,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Front Street Capital Management Inc. raised its holdings in Pfizer by 4.3% in the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 215 shares during the last quarter. Castleview Partners LLC raised its holdings in Pfizer by 2.4% in the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 287 shares during the last quarter. United Bank raised its holdings in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares during the last quarter. Compton Capital Management Inc. RI raised its holdings in Pfizer by 0.5% in the 1st quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock valued at $3,308,000 after acquiring an additional 300 shares during the last quarter. Finally, GHP Investment Advisors Inc. raised its holdings in Pfizer by 2.4% in the 4th quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock valued at $683,000 after acquiring an additional 307 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday. Finally, Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $36.88.

Pfizer Stock Performance

PFE remained flat at $25.91 during trading on Tuesday. 5,317,546 shares of the company traded hands, compared to its average volume of 42,227,086. The stock has a market capitalization of $146.72 billion, a price-to-earnings ratio of 71.94, a PEG ratio of 1.16 and a beta of 0.61. Pfizer Inc. has a 12-month low of $25.61 and a 12-month high of $41.33. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a 50 day simple moving average of $27.27 and a 200 day simple moving average of $28.84.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period last year, the business posted $1.14 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.